Treatment effect of fenofibrate varies in patients with T2DM

February 27, 2018

(HealthDay)—For individual patients with type 2 diabetes mellitus (T2DM), the effect of fenofibrate treatment varies and is larger in patients with dyslipidemia, according to a study published online Feb. 22 in Diabetes Care.

Charlotte Koopal, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues estimated the expected treatment effect of for 17,142 individual patients with T2DM. Results from the FIELD risk model were externally validated in patients from the ACCORD and SMART observational cohorts. The individual treatment effect was the difference between treated and untreated major cardiovascular event (MCVE) risk, expressed as the absolute risk reduction (ARR).

The researchers observed good calibration and moderate discrimination in ACCORD and SMART (c-statistic, 0.67 and 0.66, respectively) on external validation of the FIELD risk model. In all three studies combined, the median five-year MCVE risk was 9.4 and 6.7 percent for patients with and without , respectively. The median ARR was 2.15 and 0.22 percent for patients with and without dyslipidemia, respectively, corresponding to a number needed to treat of 47 and 455, respectively.

"In individual patients with T2DM, there is a wide range of absolute treatment effect of fenofibrate, and overall the fenofibrate treatment effect was larger in patients with dyslipidemia," the authors write. "The method of individualized treatment effect prediction of fenofibrate on MCVE risk reduction in T2DM can be used to guide clinical decision-making."

Explore further: Fenofibrate may reduce CVD in patients with DM, dyslipidemia

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Fenofibrate may reduce CVD in patients with DM, dyslipidemia

January 4, 2017
(HealthDay)—Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia, according to a study published online Dec. 28 in JAMA Cardiology.

Testosterone and fenofibrate yields strongest effect on cardio risks

June 17, 2015
(HealthDay)—A combination of testosterone and fenofibrate may offer men with high cholesterol and late-onset hypogonadism the most cardiometabolic benefit, according to a study published online May 29 in Cardiovascular ...

Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes

December 28, 2016
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated ...

Diabetes tied to higher rates of serious infection

January 23, 2018
(HealthDay)—Patients with diabetes, particularly type 1 diabetes mellitus (T1DM), are at increased risk of serious infection, according to a study published online Jan. 12 in Diabetes Care.

Intensive BP goals reduce risk of cardiovascular events

December 19, 2017
(HealthDay)—Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care.

Aspirin enhances platelet isoprostanes in type 2 diabetes

March 23, 2012
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published online March ...

Recommended for you

Belly fat promotes diabetes under orders from liver

March 21, 2018
The fat that builds up deep in the abdomen—more than any other type of body fat—raises the risk of insulin resistance and type 2 diabetes. Researchers have known that abdominal fat becomes dangerous when it becomes inflamed ...

Consuming low-calorie sweeteners may predispose overweight individuals to diabetes

March 18, 2018
Consumption of low-calorie sweeteners could promote metabolic syndrome and predispose people to prediabetes and diabetes, particularly in individuals with obesity, a new study on human fat-derived stem cells and fat samples ...

Are high blood glucose levels an effect rather than the cause of diabetes?

March 15, 2018
Insulin resistance and elevated blood glucose levels are considered to be the cause of type 2 diabetes. However, scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now provided ...

Smoking linked with higher risk of type 2 diabetes

March 15, 2018
The prevalence of diabetes has increased almost 10-fold in China since the early 1980s, with one in 10 adults in China now affected by diabetes. Although adiposity is the major modifiable risk factor for diabetes, other research ...

Social support and machine learning are at the core of a student-developed app for people with diabetes

March 14, 2018
Diabetes is the seventh leading cause of death in the U.S., and nearly 10 percent of the population suffers from this chronic disease, according to the Centers for Disease Control and Prevention.

Toxic proteins and type 2 diabetes

March 9, 2018
Nearly a half-billion people worldwide live with type 2 diabetes. Yet despite the disease's sizeable and increasing impact, its precise causes remain murky. Current scientific thinking points to two key processes: insulin ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.